Gastro-oesophageal Reflux Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are a patient of a GP (general practitioner) who is taking part in the trial.
- People who are at least 18 years old.
- People who have been taking a PPI (a type of medication that reduces stomach acid) every day for at least 8 weeks.
- People who are taking one of the following PPI medications at or above these daily doses: pantoprazole (40mg or more), omeprazole (40mg or more), lansoprazole (more than 30mg), dexlansoprazole (more than 30mg), esomeprazole (more than 20mg), or rabeprazole (more than 20mg).
- People who have a sufficient understanding of the German language to follow the trial, as assessed by their GP.
Who may not be able to join:
- People whose GP considers them to have a terminal illness with a life expectancy of less than 12 months.
- People who are not able to give informed consent to take part in the trial.
- People who have a recognised long-term medical reason for taking a PPI, such as: a history of bleeding stomach ulcer; a peptic ulcer not caused by NSAIDs or H. pylori infection; Barrett's oesophagus (a condition affecting the food pipe); severe erosive reflux disease; gastro-oesophageal reflux disease (GORD/GERD) with complications; or certain other specific conditions including Zollinger-Ellison syndrome, a type of eosinophilic oesophagitis that responds to PPIs, a form of chronic pancreatitis, or idiopathic pulmonary fibrosis (confirm with trial site).
- People who are taking two or more of the following medications, or one of the following medications combined with one or more of the listed risk factors — medications include: daily use of anti-inflammatory painkillers (NSAIDs) for more than 7 days, antiplatelet medicines (blood-thinning tablets such as aspirin), additional antiplatelet medicines (such as ticagrelor), blood-thinning medicines (anticoagulants), or steroid tablets taken for more than one month; risk factors include: a past history of a stomach or gut ulcer, being aged 75 or older, taking antidepressants known as SSRIs or SNRIs, or having a serious illness that the GP considers to increase the risk of gut bleeding (such as severe liver disease, cancer, or significant alcohol or tobacco use).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sven Streit, Prof. Dr. med. Dr. phil, University of Bern, Institute of Primary Health Care (BIHAM)
Phone: +41 31 684 58 75
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Effectiveness co-primary endpoint: prescribed PPI dose over 12 months follow-up (superiority endpoint).; Safety co-primary endpoint: upper gastrointestinal symptoms (Non-inferiority endpoint)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.